{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:44:09Z","timestamp":1766580249095,"version":"3.37.3"},"reference-count":12,"publisher":"Consilium Medicum","issue":"7","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Aim. Evaluation in real clinical practice of the effectiveness and safety of levilimab therapy in patients with highly and moderately active rheumatoid arthritis (RA).\r\nMaterials and methods. A prospective observational study (6 months) involving 35 patients with RA (29 women and 6 men, mean age 53.17\u00b113.2 years) who were treated at the Ochapovsky Regional Clinic Hospital of Krasnodar Region. All patients included in the study were prescribed the drug levilimab (Ilsira).\r\nResults. After 1 month of observation, there was a decrease in the clinical and laboratory activity of the process in the form of a decrease in the number of painful joints \u2013 17.0 (14.0; 20.0) vs 8.0 (6.0; 10.0); p=0.000001, number of swollen joints \u2013 3.0 (2.0; 4.0) vs 0.0 (0.0; 0.0); p=0.000002, reduction in pain intensity according to visual analog scale \u2013 60.0 (60.0; 70.0) mm vs 30.0 (20.0; 40.0) mm (p=0.000001). Also, by the end of the first month of therapy, there was a decrease in clinical activity indices DAS28-ESR by 43%, SDAI by 60%, CDAI by 55%. Positive dynamics of laboratory parameters were noted \u2013 a decrease in erythrocyte sedimentation rate by 76%, a decrease in C-reactive protein level by 98%. By the 6th month of therapy, a decrease in RF by 36% and ACCP by 11% was recorded, but the dynamics of these indicators did not reach statistical significance. By the end of 4 weeks of treatment, 24 (68.6%) patients showed an increase in the level of total blood cholesterol \u2013 5.1 (3.91; 6.0) mmol\/L vs 6.1 (4.99; 7.07) mmol\/L (p=0.000006), while 11 (45.8%) patients from this group had initially elevated cholesterol levels (6.4\u00b10.6 mmol\/L). In 5 (14.3%) patients, an increase in alanine aminotransferase (ALT) was recorded in the 4th week \u2013 17.0 (11.0; 25.0) U\/L vs 32.0 (22.0; 43.0) U\/L (p=0.000062) and aspartate aminotransferase (AST) \u2013 19.0 (14.0; 24.0) U\/L vs 25.0 (18.0; 36.0) U\/L (p=0.000171), in 1 (2.85%) of the patient, an increase in ALT and AST above normal was noted (ALT 144 U\/L, AST 52 U\/L), which required discontinuation of levilimab. In 2 (5.7%) patients, by the end of the 4th week a decrease in the absolute number of neutrophils was registered \u2013 3.2 (2.6; 4.0)\u00d710E9\/L vs 2.3 (2.0; 2.5)\u00d710E9\/L (p=0.002), which did not require discontinuation of treatment, since the number of cells remained more than 1\u00d710E9\/L. During treatment with levilimab 162 mg subcutaneously once a week, the proportion of patients taking prednisolone decreased from 46% at the start of therapy to 11% at the end of 6 months of therapy.\r\nConclusion. Levilimab is a highly effective drug for the treatment of patients with highly and moderately active RA and has a favorable tolerability and safety profile.<\/jats:p>","DOI":"10.26442\/00403660.2024.07.202907","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T12:29:31Z","timestamp":1722342571000},"page":"690-694","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of levilimab in the treatment of patients with rheumatoid arthritis"],"prefix":"10.26442","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6257-354X","authenticated-orcid":false,"given":"Elena V.","family":"Bolotova","sequence":"additional","affiliation":[{"name":"Kuban State Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3428-6425","authenticated-orcid":false,"given":"Evgeniya V.","family":"Yakovleva","sequence":"additional","affiliation":[{"name":"Scientific Research Institute \u2013 Ochapovsky Regional Clinic Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2283-0173","authenticated-orcid":false,"given":"Ekaterina K.","family":"Ilinykh","sequence":"additional","affiliation":[{"name":"Scientific Research Institute \u2013 Ochapovsky Regional Clinic Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6575-1274","authenticated-orcid":false,"given":"\u0422atiana A.","family":"Rassovskaya","sequence":"additional","affiliation":[{"name":"Scientific Research Institute \u2013 Ochapovsky Regional Clinic Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"ref1","unstructured":"\u0420\u0435\u0432\u043c\u0430\u0442\u043e\u0438\u0434\u043d\u044b\u0439 \u0430\u0440\u0442\u0440\u0438\u0442. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \/ \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432 \u0420\u043e\u0441\u0441\u0438\u0438. \u041c. 2021 [Revmatoidnyi artrit. Klinicheskie rekomendatsii \/ Minzdrav Rossii. Moscow. 2021 (in Rusian)]."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30173-8"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00219-2"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0419-z"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14412\/1995-4484-2017-590-599"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.32756\/0869-5490-2021-4-36-43"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.32756\/0869-5490-2021-3-67-75"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.47360\/1995-4484-2021-141-151"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.14412\/1996-7012-2021-4-13-23"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.14412\/1996-7012-2022-6-73-79"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.32756\/0869-5490-2022-4-40-47"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/634460\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/634460\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T14:41:09Z","timestamp":1733236869000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/634460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":12,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,30]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2024.07.202907","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"type":"electronic","value":"2309-5342"},{"type":"print","value":"0040-3660"}],"subject":[],"published":{"date-parts":[[2024,7,30]]}}}